Everest Medicines Limited

1952

KYG3224E1061

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2026-03-13 am EDT			5-day change	1st Jan Change
36.10 ^HKD	-2.11%		-1.74%	-2.38%

Feb. 05	Everest Medicines' Velsipity Approved for Ulcerative Colitis in China	MT
Feb. 05	Everest Medicines Limited Announces the Approval of New Drug Application in China for Velsipity®? for the Treatment of Moderate to Severe Active Ulcerative Colitis in Results and Other Business Update	CI

Everest Medicines Limited announced that it has received $280 million in funding from Immunomedics, Inc.

Published on 03/26/2023

S&P Capital IQ

EVEREST MEDICINES LIMITED

-2.11%

IMMUNOMEDICS, INC.

+0.05%

On March 27, 2023, Everest Medicines Limited closed the transaction. The company has received $280 million in the transaction.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	EVEREST MEDICINES LIMITED	36.10HKD	-2.11%	-1.74%	1.63B
	IMMUNOMEDICS, INC.	87.86USD	+0.05%	+0.34%	20.32B

Latest news about Everest Medicines Limited

Feb. 05	Everest Medicines' Velsipity Approved for Ulcerative Colitis in China	MT
Feb. 05	Everest Medicines Limited Announces the Approval of New Drug Application in China for Velsipity®? for the Treatment of Moderate to Severe Active Ulcerative Colitis in Results and Other Business Update	CI
Feb. 04	Everest Medicines Acquires License to Commercialize Kidney Drug MT1013	MT
Feb. 04	Everest Medicines inks agreement with Micot to commercialize MT1013	RE
Feb. 04	Everest Medicines Co., Ltd. Enters into an Agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd	CI
Jan. 15	Everest Medicines Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-15-2026 07:30 AM
Dec. 31	Everest Medicines says chairman purchases 30,000 shares for HK$1.139 million	RE
Dec. 29	Everest Medicines aware that generic drug to Nefecon approved by NMPA in China	RE
Dec. 29	Everest Medicines Limited Announces Approval of Generic Drug to NEFECON®?	CI
Dec. 14	Everest Medicines Executives Buy Shares	MT
Dec. 14	Everest Medicines says chairman, others purchased shares of co on Dec 12	RE
Dec. 11	Everest Medicines Limited Appoints Xin Sun as Non-Executive Director with Effect from 11 December 2025	CI
25-10-30	Certain Ordinary Shares of Everest Medicines Limited are subject to a Lock-Up Agreement Ending on 31-OCT-2025.	CI
25-10-29	Everest Medicines Acquires License to Eye Drug for $7 Million Upfront	MT
25-10-29	Everest Medicines announces agreement with Visara	RE

Chart Everest Medicines Limited

Duration

Period

1952: Dynamic Chart

Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Companyâ€™s products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.

Employees

722

Sector

Pharmaceuticals

Calendar

Mar. 26 - Earnings release - Annual 2025

More about the company